Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3b/4 Randomized Safety Endpoint Study Of 2 Doses Of Tofacitinib In Comparison To A Tumor Necrosis Factor (Tnf) Inhibitor In Subjects With Rheumatoid Arthritis

Trial Profile

Phase 3b/4 Randomized Safety Endpoint Study Of 2 Doses Of Tofacitinib In Comparison To A Tumor Necrosis Factor (Tnf) Inhibitor In Subjects With Rheumatoid Arthritis

Status: Completed
Phase of Trial: Phase III/IV

Latest Information Update: 11 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofacitinib (Primary) ; Adalimumab; Etanercept
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms ORAL Surveillance
  • Sponsors Pfizer
  • Most Recent Events

    • 03 Jun 2023 Results assessing the benefit/risk profile of tofacitinib by assessing efficacy in pts with RA with and without HxASCVD presented at the 24th Annual Congress of the European League Against Rheumatism
    • 03 Jun 2023 Results of a post-hoc analysis assessing efficacy/safety in the SOC period in patients who discontinued study drug and started SOC treatment presented at the 24th Annual Congress of the European League Against Rheumatism
    • 05 Dec 2022 Results of post hoc analysis, evaluating malignancies and their associations with baseline risk factors and cardiovascular risk scores with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis , published in the Annals of the Rheumatic Diseases
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top